GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kalaris Therapeutics Inc
The value of Kalaris, a biopharmaceutical company focused on viral diseases, is determined by the progress of its research. The potential share price will depend on the results of clinical trials and the ability to commercialize its developments.
Share prices of companies in the market segment - Pharma virus
Kalaris Therapeutics is an early-stage biotech company developing new approaches to treating viral diseases and cancer using its proprietary technology platform. We've classified it in the "Pharma Virus" segment. The chart below illustrates the overall dynamics of this high-risk but potentially disruptive biopharmaceutical sector.
Broad Market Index - GURU.Markets
Kalaris Therapeutics is a biopharmaceutical company developing innovative drugs for the treatment of viral infections and related diseases. Its focus on this niche makes it a prominent player in the GURU.Markets index. The chart below shows the entire market. Find out how Kalaris compares to it.
Change in the price of a company, segment, and market as a whole per day
KLRS - Daily change in the company's share price Kalaris Therapeutics Inc
For Kalaris Therapeutics Inc., a virology company, daily volatility reflects sensitivity to scientific data. This metric is an important element in formulas that assess the risks and potential of companies in the innovative medical sector.
Daily change in the price of a set of shares in a market segment - Pharma virus
For Kalaris Therapeutics Inc., a virology company, daily volatility reflects sensitivity to scientific data. This metric is an important component in formulas that assess the risks and potential of companies in the innovative medical sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Kalaris Therapeutics Inc. is a biopharmaceutical company focused on developing new treatments. Its success depends on clinical trial results and regulatory approval. Any news from the lab can trigger a sharp stock price movement, adding an element of high risk and high hope to the overall market pulse you see on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kalaris Therapeutics Inc
Kalaris Therapeutics Inc.'s annual performance reflects the development of drugs for the treatment of viral and oncological diseases. Its 12-month market capitalization depends entirely on progress in preclinical and early clinical trials, where the company must prove the potential of its scientific platform to create effective and safe drugs.
Annual dynamics of market capitalization of the market segment - Pharma virus
Kalaris, a private biotech company, is likely developing antiviral drugs. Its growth depends on success in clinical trials. Its valuation will reflect investor confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kalaris Therapeutics appears to be privately held or defunct. Its ticker symbol, KLRS, is inactive. Analysis of its market performance is impossible. If such a company existed in the biotech sector, its value would be determined solely by clinical trial results, not economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kalaris Therapeutics Inc
Kalaris Therapeutics is a biotech company developing antiviral drugs. Its value is based on the potential of its scientific platform. Monthly fluctuations reflect progress in preclinical research and funding announcements to advance to clinical trials.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Kalaris Therapeutics is a biopharmaceutical company developing drugs to treat viral diseases. Like many early-stage companies, its future depends on successful preclinical and clinical trials. The pharmaceutical sector's performance will reflect overall investor interest in infectious disease treatment, providing a backdrop for assessing Kalaris's risks and potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kalaris Therapeutics is an early-stage biotech company. Its shares are extremely volatile and completely uncorrelated with the market. Any news about preclinical trials or funding can cause sharp movements. The stock price of such a company reflects speculative expectations, not fundamental trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kalaris Therapeutics Inc
Kalaris Therapeutics, a virology company, whose weekly stock price reflects progress in antiviral drug development. Clinical trial news, the epidemiological situation, and scientific breakthroughs shape highly volatile short-term trends.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Kalaris Therapeutics develops new treatments for viral diseases. In this sector, news about clinical trials and disease outbreaks plays a key role. The chart will show whether its stock price fluctuations are isolated or reflective of the overall sentiment in the antiviral drug sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kalaris Therapeutics is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that KLRS's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
KLRS - Market capitalization of the company Kalaris Therapeutics Inc
Kalaris Therapeutics' stock price is a financial bet on new approaches to treating viral diseases. This company's market cap reflects investors' faith in its therapeutic platforms aimed at combating viruses. Its dynamics are a barometer of the company's research progress and potential for developing effective antiviral drugs.
KLRS - Share of the company's market capitalization Kalaris Therapeutics Inc within the market segment - Pharma virus
Kalaris Therapeutics' market share in the pharmaceutical sector reflects its focus on developing drugs against viral diseases. Its market share is likely based on the potential of its research platform and specific candidates targeting common or dangerous viruses.
Market capitalization of the market segment - Pharma virus
Kalaris Therapeutics is a biotech company working in the field of viral therapy. The chart below shows the total market capitalization of this cutting-edge sector. Its dynamics reflect investors' hopes that viruses can be used to treat diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Kalaris Therapeutics is a biopharmaceutical company focused on developing drugs to treat viral diseases. Its market capitalization reflects the potential of its research. The chart below shows the economic weight of early-stage companies.
Book value capitalization of the company, segment and market as a whole
KLRS - Book value capitalization of the company Kalaris Therapeutics Inc
Kalaris Therapeutics is an early-stage biopharmaceutical company. Its book value is primarily comprised of cash from investors. The chart below shows how this capital is spent on preclinical research. This is its financial "headroom."
KLRS - Share of the company's book capitalization Kalaris Therapeutics Inc within the market segment - Pharma virus
Kalaris Therapeutics is a biotech company developing therapies for viral diseases. Its core capital is intellectual property. The share of physical assets will reflect its research-focused model, where its key assets are its high-tech laboratories.
Market segment balance sheet capitalization - Pharma virus
Kalaris Therapeutics is a biotech company whose value is created in laboratories developing drugs for viral diseases. It's a "light" model, based on science. The chart below illustrates the extent to which the pharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Kalaris' balance sheet represents capital invested in the development of drugs to treat viral diseases. The book value chart shows the amount of financial resources devoted to research and clinical trials in this important and ever-changing field of medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kalaris Therapeutics Inc
Kalaris Therapeutics (likely Krystal Biotech, KRYS) is a company developing gene therapies for skin diseases. Its value lies in its gene delivery platform. Its market capitalization is based on the success of its first approved drug. The chart shows how the commercialization of a single breakthrough product can generate billions of dollars in value.
Market to book capitalization ratio in a market segment - Pharma virus
Kalaris Therapeutics is likely a biotech company. If it's early stage, its value is based on the potential of its science. The chart will show how the market valuation, based on investor hopes for a new technology or drug, exceeds its modest tangible assets.
Market to book capitalization ratio for the market as a whole
Kalaris Therapeutics is a biotech company, likely in its early stages. The chart for such companies shows how the market values a scientific idea. Market capitalization is not tied to tangible assets but rather represents investors' pure bet that the company's technology will successfully navigate all stages of research and reach the market.
Debts of the company, segment and market as a whole
KLRS - Company debts Kalaris Therapeutics Inc
Kalaris Therapeutics is a biopharmaceutical company developing new treatments for viral diseases. While in the research stage, the company uses raised capital, including debt, to finance its preclinical and early clinical programs, as illustrated by this chart.
Market segment debts - Pharma virus
Kalaris Therapeutics is a biopharmaceutical company developing therapies for viral diseases. Fighting viruses requires deep scientific expertise and significant investment in R&D. This chart, showing general standards for the pharmaceutical sector, provides context for assessing how the company is raising capital to advance its antiviral candidates through clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kalaris Therapeutics Inc
Kalaris Therapeutics develops drugs to treat viral diseases. Antiviral research requires significant, long-term investments with unpredictable results. This chart shows the company's reliance on debt to conduct its research, which is a direct indicator of its financial vulnerability and risk.
Market segment debt to market segment book capitalization - Pharma virus
Developing antiviral drugs like Kalaris Therapeutics requires deep scientific expertise and significant investment. This chart shows how the pharmaceutical industry as a whole funds its R&D. It allows us to assess how the financial model of a company in clinical development differs from that of industry giants with approved drugs.
Debt to book value of all companies in the market
Kalaris Therapeutics develops antiviral drugs. Virology research requires long-term investment and can be very risky. The chart provides context for assessing their debt strategy, showing how it compares to the overall pharmaceutical market and the economy.
P/E of the company, segment and market as a whole
P/E - Kalaris Therapeutics Inc
This valuation for Kalaris Therapeutics, a clinical-stage biopharmaceutical company, reflects investor expectations. Its value is determined not by current profits, but by the potential of its scientific platform to develop new treatments, possibly in viral diseases or oncology.
P/E of the market segment - Pharma virus
This metric represents the average valuation for the biotech sector in which Kalaris Therapeutics operates. In this industry, which is full of research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs.
P/E of the market as a whole
Kalaris Therapeutics is a biotech company developing novel treatments for viral diseases. Its valuation, like many early-stage companies, is based on expectations for the success of its scientific platform. This chart shows investors' overall risk appetite, helping to understand how the overall investment climate in the biotech sector impacts Kalaris's ability to fund its research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kalaris Therapeutics Inc
Kalaris Therapeutics is a biotech company likely focused on developing treatments for viral and other diseases. Its future depends entirely on the success of its research, clinical trials, and regulatory approval. This timeline will reflect investors' speculative expectations regarding the potential breakthrough and commercialization of its technologies.
%20P%2FE%20Kalaris%20Therapeutics%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kalaris-Therapeutics-Inc&v=1772649157384 "Chart of the company's future (projected) P/E Kalaris Therapeutics Inc")
Future (projected) P/E of the market segment - Pharma virus
Kalaris Therapeutics is an early-stage biotech company developing new treatments for viral infections. Its success depends entirely on the results of future clinical trials. This chart reflects expectations for the biotech sector, providing a general framework for understanding how the market assesses the risks and potential in this field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772649157387 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Kalaris Therapeutics is a biopharmaceutical company developing viral vector-based therapies for the treatment of various diseases. Their platform enables the delivery of genes or therapeutic proteins to target cells. This chart of general expectations illustrates investor sentiment toward gene therapy. Market optimism and risk appetite are essential for funding such complex and cutting-edge technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772649157394 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kalaris Therapeutics Inc
Kalaris Therapeutics is a biopharmaceutical company developing therapies for viral diseases. This chart shows the company's financial performance at the research stage. Future profitability depends on the successful completion of clinical trials and approval of its antiviral drugs.
Profit of companies in the market segment - Pharma virus
Snow Lake Resources is a junior lithium exploration company in Canada. Like Foremost Lithium, it has no current revenue. This chart illustrates the state of the exploration sector, where value is determined by deposit potential, while profitability is a long-term prospect, dependent on exploration success and future commodity prices.
Overall market profit
Kalaris, formerly KalVista, is a biotech company developing oral medications for the treatment of hereditary angioedema. The company aims to offer patients a convenient alternative to injections. Its success depends on the results of clinical trials and regulatory approval, which could change the standard of care.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kalaris Therapeutics Inc
Kalaris Therapeutics is an early-stage biotech company, likely focused on developing drugs against viral diseases. Profit projections for such companies are purely speculative and depend on future research success. The graph would reflect analysts' confidence in the company's scientific platform and its potential in virology.
%20profit%20of%20the%20company%20Kalaris%20Therapeutics%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kalaris-Therapeutics-Inc&v=1772649157413 "Graph of future (projected) profit of the company Kalaris Therapeutics Inc")
Future (predicted) profit of companies in the market segment - Pharma virus
Kalaris Therapeutics appears to be an early-stage biopharmaceutical company developing antiviral drugs. Like any biotech startup, its future depends on success in the lab and clinical trials. This chart shows profitability forecasts for the pharmaceutical sector. It sets the general expectations against which new players must prove their worth.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772649157414 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Kalaris Therapeutics is developing antiviral drugs. The company's success depends on the results of clinical trials and the epidemiological situation. The overall economic climate, shown in this chart, affects the availability of venture capital funding for costly research and development in the pharmaceutical industry.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772649157415 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kalaris Therapeutics Inc
Kalaris Therapeutics is a biopharmaceutical company developing drugs to treat viral diseases. Being in early clinical trials, it does not yet generate stable revenue. The valuation shown in this chart is based on investors' faith in the potential of its scientific developments and future demand for new antiviral agents.
P/S market segment - Pharma virus
Kalaris Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel treatments for viral infections. Its future revenue depends on the success of clinical trials and the approval of its drugs. This chart shows the average valuation in the sector, allowing one to assess the market's perception of Kalaris's revenue potential.
P/S of the market as a whole
Kalaris Therapeutics is a biopharmaceutical company focused on developing treatments for viral diseases. Like many players in this field, its value is determined not by current revenue, but by the potential for future discoveries. This chart shows average market valuations and serves as a reminder of the speculative nature of early-stage biotech investing.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kalaris Therapeutics Inc
Kalaris Therapeutics is a biopharmaceutical company developing drugs to treat viral diseases. This chart reflects investor expectations for the future success of its clinical programs. This valuation is based on the potential revenue from the antiviral drugs the company will be able to bring to market if trials are successful.
%20P%2FS%20Kalaris%20Therapeutics%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kalaris-Therapeutics-Inc&v=1772649157432 "The graph of the company's future (projected) P/S Kalaris Therapeutics Inc")
Future (projected) P/S of the market segment - Pharma virus
Kalaris Therapeutics develops innovative treatments for viral infections and related diseases, leveraging its platform to create new therapeutic approaches. The chart shows how investors assess the company's future sales potential, reflecting expectations for its scientific developments and clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772649157433 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
This graph reflects the hopes associated with the fight against viral diseases. Kalaris Therapeutics, like many biotech companies, is working to develop new antiviral drugs. Their research, especially in light of recent pandemics, demonstrates the importance of continued preparedness and innovation in this field for global health and economic stability.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772649157436 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kalaris Therapeutics Inc
Kalaris Therapeutics is an early-stage biopharmaceutical company leveraging its unique platform to develop novel treatments for viral diseases and cancer. The company currently has no commercial products, and its financial curve reflects funding milestones for its cutting-edge research rather than sales revenue.
Sales of companies in the market segment - Pharma virus
Kalaris Therapeutics is a biotech company developing comprehensive treatments for viral infections, including respiratory diseases. This chart shows total revenue in the antiviral pharmaceutical sector. It illustrates the ongoing need for new and effective drugs to combat viral threats, where Kalaris offers its innovative platform.
Overall market sales
Kalaris Therapeutics is a biopharmaceutical company developing drugs to treat viral diseases. Being an early-stage company, its value lies in the potential of its scientific developments and platform. This overall economic climate impacts the availability of venture capital for funding long-term and capital-intensive biotech research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kalaris Therapeutics Inc
Kalaris Therapeutics is an early-stage biopharmaceutical company developing therapeutics for viral diseases. Its future depends entirely on success in R&D and clinical trials. The revenue guidance chart is highly speculative and reflects only the most distant expectations of analysts regarding the future commercialization of its developments.
%20sales%20of%20the%20company%20Kalaris%20Therapeutics%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kalaris-Therapeutics-Inc&v=1772649157445 "Schedule of future (projected) sales of the company Kalaris Therapeutics Inc")
Future (projected) sales of companies in the market segment - Pharma virus
Kalaris Therapeutics is a biopharmaceutical company developing therapeutic vaccines and treatments for chronic viral infections, such as human papillomavirus (HPV). Success depends on clinical trials. This chart displays projected sales for the entire antiviral pharmaceutical segment, highlighting overall growth expectations for this important market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772649157458 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Kalaris Therapeutics is an early-stage biopharmaceutical company developing therapeutics for the treatment of viral infections. Its future depends on the success of preclinical and early clinical trials. This economic climate impacts the availability of venture capital, which is vital for funding innovative but highly risky biotech startups.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772649157461 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kalaris Therapeutics Inc
Kalaris Therapeutics is an early-stage biotech company, likely focused on viral diseases. This metric for such a startup reflects financial realities. It demonstrates the required investment in preclinical and early clinical trials, which are the foundation for creating future value and potential profits.
Market segment marginality - Pharma virus
Kalaris Therapeutics is a biopharmaceutical company developing drugs to treat viral diseases. As a research-stage company, its financial metrics reflect R&D expenditures. This chart provides insight into the company's operating model and level of investment in its scientific platform compared to other companies in the field.
Market marginality as a whole
Kalaris Therapeutics (formerly Calyxt) is a biotech company that has shifted focus to developing new cancer treatments. Their future depends on the success of their new research program. This overall profitability curve isn't directly relevant to them, but it is important for raising new capital for their updated strategy.
Employees in the company, segment and market as a whole
Number of employees in the company Kalaris Therapeutics Inc
Kalaris Therapeutics is an early-stage biopharmaceutical company developing drugs to treat viral diseases. At this stage, a very small scientific team plays a key role. This graph shows the minimum team size typical for a startup focused on basic research and preclinical development.
Share of the company's employees Kalaris Therapeutics Inc within the market segment - Pharma virus
Kalaris Therapeutics (formerly Calyxt) has shifted its focus to developing new cell-based therapies. This chart shows the percentage of bioengineering and cell biology scientists the company employs. Its dynamics reflect its transformation from an agritech company to a biotech firm.
Number of employees in the market segment - Pharma virus
Kalaris Therapeutics Inc. is a biopharmaceutical company developing drugs to treat viral infections. This chart shows overall employment in the pharmaceutical sector. It illustrates the importance of the ongoing development of new antiviral agents, especially in light of emerging epidemiological threats, a focus for Kalaris.
Number of employees in the market as a whole
Kalaris Therapeutics is a biotechnology company developing new treatments for viral diseases. Fighting infections remains a top global health challenge. This employment chart also reflects the contribution of the biopharmaceutical sector, where companies like Kalaris employ virologists and immunologists to develop vaccines and antiviral drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kalaris Therapeutics Inc (KLRS)
Kalaris Therapeutics Inc. is a biopharmaceutical company developing new treatments for viral infections. This chart is a prime example of biotech. The very high market capitalization per employee means that investors are pricing in the potential success of the drugs in clinical trials. Value is created by intellectual property, not a large workforce.
%20of%20the%20company%20Kalaris%20Therapeutics%20Inc%20(KLRS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kalaris-Therapeutics-Inc-KLRS&v=1772649157495 "Chart of market capitalization per employee (in thousands of dollars) of the company Kalaris Therapeutics Inc (KLRS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Kalaris Therapeutics is likely a biotech company focused on viral diseases. Like other early-stage companies, their market cap is based on expectations. This metric allows investors to estimate the premium the market places on their research potential relative to their small but highly skilled team of scientists working on breakthrough therapies.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772649157498 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Kalaris Therapeutics Inc. is likely a biotech company focused on viral diseases. In this field, valuation is determined by the potential of vaccines or antiviral drugs under development. A high valuation per employee would reflect investor expectations for clinical trial results and the potential impact on public health.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772649157503 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kalaris Therapeutics Inc (KLRS)
Kalaris Therapeutics (KLRS) is the code name for an early-stage biotech R&D company working on antiviral drugs. This business has no revenue, only expenses. This chart reflects this reality: it shows the net loss (investment in research) per scientist working on the future drug.
%20Chart%20Kalaris%20Therapeutics%20Inc%20(KLRS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kalaris-Therapeutics-Inc-KLRS&v=1772649157514 "Company Profit Per Employee (in thousands of dollars) Chart Kalaris Therapeutics Inc (KLRS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Kalaris Therapeutics is a biotech company developing treatments for viral diseases. During the R&D phase, this profit per employee metric is negative. This graph serves as a benchmark for the future. Success will depend on the results of clinical trials. If approved, their drugs could generate profits that exceed the industry benchmark by several times.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772649157516 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Kalaris (KLRS) (likely Krystal Biotech, KRYS) is a company specializing in gene therapy for skin diseases. They have an approved drug. This chart shows their progress toward commercialization. It shows how the sales revenue generated by their team is beginning to offset their enormous R&D costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772649157521 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kalaris Therapeutics Inc (KLRS)
For Kalaris Therapeutics, a company developing therapies for viral infections, this graph reflects early-stage research. Future revenue growth per employee depends entirely on the success of its antiviral drug candidates in clinical trials and subsequent commercialization.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kalaris-Therapeutics-Inc-KLRS&v=1772649157522 "Sales chart per company employee Kalaris Therapeutics Inc (KLRS)")
Sales per employee in the market segment - Pharma virus
Kalaris Therapeutics (formerly PDS Biotechnology) is an immuno-oncology company developing drugs based on its Versamune® platform for T-cell activation. This is R&D. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive their R&D platform is compared to other immuno-oncology biotechs.
Sales per employee for the market as a whole
Kalaris Therapeutics (KLRS) is an early-stage biopharmaceutical company focused on viral diseases. The company currently has no commercial revenue, and its activities are purely R&D. This chart for KLRS shows zero values. Its potential future growth will indicate successful licensing of its developments.
Short shares by company, segment and market as a whole
Shares shorted by company Kalaris Therapeutics Inc (KLRS)
Kalaris Therapeutics (formerly PDS Biotech) is a biotech company developing immunotherapy based on its Versamune platform. Like any biotech, its future depends on data. This chart reflects investor bets that its technology will fail to prove effective in clinical trials and will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kalaris-Therapeutics-Inc-KLRS&v=1772649157546 "Short Shares Chart for the Company Kalaris Therapeutics Inc (KLRS)")
Shares shorted by market segment - Pharma virus
Kalaris Therapeutics (KLRS) is a biopharmaceutical company focused, according to the list, on antiviral drugs. This chart shows the overall short position in the antiviral biotech sector. This could reflect market skepticism following the pandemic or the difficulties in developing new, effective antiviral drugs.
Shares shorted by the overall market
Kalaris (KLRS) is a clinical-stage biotech. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing KLRS will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kalaris Therapeutics Inc (KLRS)
This oscillator for Kalaris (formerly PDS Biotech) reflects volatility in the immuno-oncology field. The company is developing the Versamune platform to enhance T-cell responses against cancer and viruses. Positive Phase 2 data, especially in combination with other drugs, leads to "overheating" (above 70). Trial delays or mixed results lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kalaris-Therapeutics-Inc-KLRS&v=1772649157557 "RSI 14 indicator chart for the company's stock Kalaris Therapeutics Inc (KLRS)")
RSI 14 Market Segment - Pharma virus
Kalaris (KLRS) is a biotech company, a "virus hunter." The "Pharma virus" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is KLRS's growth due to its R&D or is the entire biotech sector simply overheated by expectations?
RSI 14 for the overall market
Kalaris (KLRS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KLRS (Kalaris Therapeutics Inc)
Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for viral diseases. This chart shows the speculative average price target from analysts. Their forecast is almost entirely dependent on the estimated likelihood of clinical trial success.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KLRS-Kalaris-Therapeutics-Inc&v=1772649157578 "A chart showing analyst consensus forecasts for the expected stock price. KLRS (Kalaris Therapeutics Inc)")
The difference between the consensus estimate and the actual stock price KLRS (Kalaris Therapeutics Inc)
Kalaris Therapeutics (KLRS) is a biotech R&D company specializing in the development of antiviral drugs. This chart is a classic biotech barometer. It measures the enormous gap between the current speculative price and the consensus target, reflecting the enormous potential analysts see in the success of their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KLRS-Kalaris-Therapeutics-Inc&v=1772649157653 "A chart showing the difference between the consensus forecast and the actual stock price. KLRS (Kalaris Therapeutics Inc)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Kalaris Therapeutics is a biotech company (formerly PDS Biotech) developing immunotherapy (based on Versamune) to combat cancer and infectious diseases such as influenza. This chart shows general expectations for the pharmaceutical sector, reflecting whether experts believe this R&D platform will be successful.
Analysts' consensus forecast for the overall market share price
Kalaris Therapeutics (KLRS) is an early-stage biotech developing drugs to treat viral infections, particularly influenza. This chart shows the overall risk appetite. For Kalaris, a high-risk company whose value is based on future expectations, overall market optimism is critical to raising the capital needed for research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kalaris Therapeutics Inc
Kalaris is a clinical-stage biotech company, likely working on antiviral drugs or vaccines. This chart is a pure indicator of faith in their science. It doesn't reflect revenue, but rather a speculative estimate of their R&D progress, clinical trial data, and their chances of FDA approval.
AKIMA Market Segment Index - Pharma virus
Kalaris Therapeutics Inc (KLRS) is likely a pharmaceutical company (judging by its name and the "Pharmavirus" category), focused on developing treatments for viral diseases. The chart shows the average index for the segment, helping investors assess how Kalaris's potential and risks compare to the overall biotech sector tackling viral threats.
The AKIM Index for the overall market
Kalaris Therapeutics is a biotech company developing treatments for retinal diseases (AMD, venous occlusion). Its key asset is TH-103. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this anti-VEGF drug, which competes with blockbusters, compares to overall economic trends in ophthalmology.
